Evidence map›Paper›PMID 27407134›Full record

ReviewNeuro-oncology2016

Stereotactic modulation of blood-brain barrier permeability to enhance drug delivery.

Geoff Appelboom, Alexandre Detappe, Melissa LoPresti, Sijumon Kunjachan, Stefan Mitrasinovic, Serge Goldman, Steve D Chang, Olivier Tillement

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Neuro-oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Geoff AppelboomDepartment of Neurosurgery, Stanford Medical Center, Stanford, California (G.A., S.D.C.); Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts (A.D., S.K.); Institut Lumière Matière, Université Claude Bernard Lyon 1, Villeurbanne, France (A.D., O.T.); Department of Neurosurgery, Baylor College of Medicine, Houston, Texas (M.L.); Department of Neurological Surgery, Columbia University Medical Center, New York, New York (S.M.); Department of Nuclear Medicine, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium (S.G.).
Alexandre DetappeDepartment of Neurosurgery, Stanford Medical Center, Stanford, California (G.A., S.D.C.); Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts (A.D., S.K.); Institut Lumière Matière, Université Claude Bernard Lyon 1, Villeurbanne, France (A.D., O.T.); Department of Neurosurgery, Baylor College of Medicine, Houston, Texas (M.L.); Department of Neurological Surgery, Columbia University Medical Center, New York, New York (S.M.); Department of Nuclear Medicine, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium (S.G.).
Melissa LoPrestiDepartment of Neurosurgery, Stanford Medical Center, Stanford, California (G.A., S.D.C.); Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts (A.D., S.K.); Institut Lumière Matière, Université Claude Bernard Lyon 1, Villeurbanne, France (A.D., O.T.); Department of Neurosurgery, Baylor College of Medicine, Houston, Texas (M.L.); Department of Neurological Surgery, Columbia University Medical Center, New York, New York (S.M.); Department of Nuclear Medicine, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium (S.G.).
Sijumon KunjachanDepartment of Neurosurgery, Stanford Medical Center, Stanford, California (G.A., S.D.C.); Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts (A.D., S.K.); Institut Lumière Matière, Université Claude Bernard Lyon 1, Villeurbanne, France (A.D., O.T.); Department of Neurosurgery, Baylor College of Medicine, Houston, Texas (M.L.); Department of Neurological Surgery, Columbia University Medical Center, New York, New York (S.M.); Department of Nuclear Medicine, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium (S.G.).
Stefan MitrasinovicDepartment of Neurosurgery, Stanford Medical Center, Stanford, California (G.A., S.D.C.); Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts (A.D., S.K.); Institut Lumière Matière, Université Claude Bernard Lyon 1, Villeurbanne, France (A.D., O.T.); Department of Neurosurgery, Baylor College of Medicine, Houston, Texas (M.L.); Department of Neurological Surgery, Columbia University Medical Center, New York, New York (S.M.); Department of Nuclear Medicine, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium (S.G.).
Serge GoldmanDepartment of Neurosurgery, Stanford Medical Center, Stanford, California (G.A., S.D.C.); Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts (A.D., S.K.); Institut Lumière Matière, Université Claude Bernard Lyon 1, Villeurbanne, France (A.D., O.T.); Department of Neurosurgery, Baylor College of Medicine, Houston, Texas (M.L.); Department of Neurological Surgery, Columbia University Medical Center, New York, New York (S.M.); Department of Nuclear Medicine, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium (S.G.).
Steve D ChangDepartment of Neurosurgery, Stanford Medical Center, Stanford, California (G.A., S.D.C.); Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts (A.D., S.K.); Institut Lumière Matière, Université Claude Bernard Lyon 1, Villeurbanne, France (A.D., O.T.); Department of Neurosurgery, Baylor College of Medicine, Houston, Texas (M.L.); Department of Neurological Surgery, Columbia University Medical Center, New York, New York (S.M.); Department of Nuclear Medicine, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium (S.G.).
Olivier TillementDepartment of Neurosurgery, Stanford Medical Center, Stanford, California (G.A., S.D.C.); Department of Radiation Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts (A.D., S.K.); Institut Lumière Matière, Université Claude Bernard Lyon 1, Villeurbanne, France (A.D., O.T.); Department of Neurosurgery, Baylor College of Medicine, Houston, Texas (M.L.); Department of Neurological Surgery, Columbia University Medical Center, New York, New York (S.M.); Department of Nuclear Medicine, Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium (S.G.).

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug delivery in the CNS is limited by endothelial tight junctions forming the impermeable blood-brain barrier. The development of new treatment paradigms has previously been hampered by the restrictiveness of the blood-brain barrier to systemically administered therapeutics. With recent advances in stereotactic localization and noninvasive imaging, we have honed the ability to modulate, ablate, and rewire millimetric brain structures to precisely permeate the impregnable barrier. The wide range of focused radiations offers endless possibilities to disrupt endothelial permeability with different patterns and intensity following 3-dimensional coordinates offering a new world of possibilities to access the CNS, as well as to target therapies. We propose a review of the current state of knowledge in targeted drug delivery using noninvasive image-guided approaches. To this end, we focus on strategies currently used in clinics or in clinical trials such as targeted radiotherapy and magnetic resonance guided focused ultrasound, but also on more experimental approaches such as magnetically heated nanoparticles, electric fields, and lasers, techniques which demonstrated remarkable results both in vitro and in vivo. We envision that biodistribution and efficacy of systemically administered drugs will be enhanced with further developments of these promising strategies. Besides therapeutic applications, stereotactic platforms can be highly valuable in clinical applications for interventional strategies that can improve the targetability and efficacy of drugs and macromolecules. It is our hope that by showcasing and reviewing the current state of this field, we can lay the groundwork to guide future research in this realm.

Indexed as

Stereotaxic TechniquesAnimalsBlood-Brain BarrierCapillary PermeabilityDrug Delivery SystemsHumansLaser TherapyMagnetic Field TherapyNanoparticlesRadiosurgeryUltrasonic Therapyelectroporationfocused ultrasoundmicrobubblesphotodynamic therapyvascular permeability

Identifiers

PMID27407134
PMCPMC5744238

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.